Blood Transfusion Diagnostics Market Size was valued at USD 4.75 Billion in 2023. The Global Blood Transfusion Diagnostics industry is projected to grow from USD 5.03 Billion in 2024 to USD 7.89 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.89% during the forecast period (2024 - 2032).
Blood transfusion diagnostics is the intravenous transfer of blood or blood products. Blood transfusions can be used to replace blood components that have been lost. The most common blood components transfused include red blood cells, white blood cells, platelets, clotting factors, and plasma. During an emergency or a serious case of massive blood loss, these blood components are crucial to laboratories and hospitals. When hemoglobin levels fall below 100g/L, RBC transfusion is required. Before being transfused, blood from a donor must be checked for a variety of infectious diseases.
Blood transfusion demand is being driven by the rising prevalence of chronic and infectious diseases such as severe anemia, cancer, hemophilia, kidney disease, liver disease, severe infection, sickle cell disease, and thrombocytopenia, as well as the introduction of technologically advanced products. As a result, blood transfusion diagnostics play a vital role in preventing infection in both the recipient and the healthcare workers. The expansion of this market is fueled by rising infectious disease prevalence, an increase in the number of blood transfusion procedures, the need for screened blood products, and increased campaigning or awareness campaigns. The demand for blood and blood products outnumbers the supply, adding to the Blood Transfusion Diagnostics market's expansion.
November 2023
Versiti, an organization renowned for its pioneering efforts in blood health innovation, declared today the procurement of Pearl Pathways, a favored collaborator and trusted advisor in the life sciences industry, to facilitate the development of innovative and expedited products.
Pearl Pathways, headquartered in Indianapolis, is a comprehensive life science consulting firm that specializes in delivering specialized CRO services, regulatory affairs, and quality compliance. An additional AHRPP-accredited, independent IRB oversees all facets of human research at Pearl. With regard to life science service providers and biopharmaceutical, medical device, and diagnostic companies, the organization provides comprehensive support in terms of clinical, regulatory, and quality compliance requirements.
"Pearl Pathways brings deep expertise in life science product development, which ultimately leads to getting life-saving devices, diagnostics, and therapeutics to patients faster," said Versiti President and Chief Executive Officer Chris Miskel. "By engaging in this strategic collaboration, Versiti Clinical Trials enhances the range and variety of its research-based solutions while also fortifying its spectrum of capabilities to facilitate earlier disease cures."
By enabling Versiti to assist clinical trials sponsors earlier and further along the development pathway, while continuing to provide services until regulatory approval and commercialization, Pearl Pathways expands the organization's scope.
This transaction further enhances the functionalities established by Versiti's Diagnostic Laboratories. It transpires subsequent to the organization's procurement of Quantigen, a specialized laboratory situated in Fishers, Indiana, and Cenetron Central Laboratories and Salus IRB, both based in Texas, earlier this year.
"The Pearl Pathways staff is ecstatic to announce their entry into Versiti." With the aim of enhancing patient care, Versiti has supported fundamental and translational research for decades. "Pearl and Versiti will work together to accelerate the development of the next generation of therapies and devices," stated Gretchen Bowker, founder of Pearl Pathways.
More than 2,300 individuals are employed by Versiti, which has offices in Wisconsin, Illinois, Indiana, Michigan, Ohio, and Texas, in addition to its Milwaukee headquarters.
Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.
Key Players
The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products.
On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.
Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.
Recent Development
Ortho Clinical Diagnostics introduced the ORTHO VISION Swift and ORTHO VISION Max Swift analyzers in April 2021. These analyzers provide laboratory networks with more processing power and enhanced data security. Hemanext, a blood storage technology company, said in September 2021 that it would raise USD 15 million in a new series A fundraising round and USD 100 million from private equity. Its goal is to spread the Hemanext One System's processes all over the world. The technology has a CE designation, which means it can be sold throughout Europe.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 7.89 Billion |
| Compound Annual Growth Rate (CAGR) | 5.89% (2024-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2020 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, Product, Route of Administration, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Immucor (U.S), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter |
| Key Market Opportunities | · New product developments, and research and developments in the Blood Transfusion Diagnostics market. |
| Key Market Drivers | . Rising infectious disease prevalence |
Blood Transfusion Diagnostics Market Highlights:
Frequently Asked Questions (FAQ) :
Global Blood Transfusion Diagnostics Market is expected to be valued at USD 7.89 Billion by 2032
Leading players in the Blood Transfusion Diagnostics Market include Roche Diagnostics, Thermo Fisher, and Grifols, among others.
Increasing volume of blood transfusions is likely to be a key driver for the Blood Transfusion Diagnostics Market.
Americas are the largest Blood Transfusion Diagnostics Market.
Blood Transfusion Diagnostics Market is expected to exhibit a strong 5.89% by 2024-2032.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
